Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements ; day:2 ; month:9 ; year:2021 ; pages:1-10
European journal of nuclear medicine and molecular imaging ; (2.9.2021), 1-10
- Creator
-
Eertink, J. J.
Arens, A. I. J.
Huijbregts, J. E.
Celik, F.
Keizer, B. de
Stroobants, S.
Jong, D. de
Wiegers, S. E.
Zwezerijnen, G. J. C.
Burggraaff, C. N.
Boellaard, R.
Vet, H. C. W. de
Hoekstra, O. S.
Lugtenburg, P. J.
Chamuleau, M. E. D.
Zijlstra, J. M.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00259-021-05498-7
- URN
-
urn:nbn:de:101:1-2021111519501523899737
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Eertink, J. J.
- Arens, A. I. J.
- Huijbregts, J. E.
- Celik, F.
- Keizer, B. de
- Stroobants, S.
- Jong, D. de
- Wiegers, S. E.
- Zwezerijnen, G. J. C.
- Burggraaff, C. N.
- Boellaard, R.
- Vet, H. C. W. de
- Hoekstra, O. S.
- Lugtenburg, P. J.
- Chamuleau, M. E. D.
- Zijlstra, J. M.
- SpringerLink (Online service)
Other Objects (12)
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
![Charakterisierung des VL-Gen-Rearrangements [VL-Gen-Rearrangements] in c-myc-transformierten Abelson-pre-B-Zellinien](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Charakterisierung des VL-Gen-Rearrangements [VL-Gen-Rearrangements] in c-myc-transformierten Abelson-pre-B-Zellinien
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
Novel chromatin interactions by structural rearrangements and aberrant enhancer functions drive oncogenic programs in unfavorable neuroblastoma
Novel chromatin interactions by structural rearrangements and aberrant enhancer functions drive oncogenic programs in unfavorable neuroblastoma
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
Charakterisierung des VL-Gen-Rearrangements [VL-Gen-Rearrangements] in c-myc-transformierten Abelson-pre-B-Zellinien
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
Novel chromatin interactions by structural rearrangements and aberrant enhancer functions drive oncogenic programs in unfavorable neuroblastoma
Novel chromatin interactions by structural rearrangements and aberrant enhancer functions drive oncogenic programs in unfavorable neuroblastoma
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
Charakterisierung des VL-Gen-Rearrangements [VL-Gen-Rearrangements] in c-myc-transformierten Abelson-pre-B-Zellinien
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Round-robin testing for LMO2 and MYC as immunohistochemical markers to screen MYC rearrangements in aggressive large B-cell lymphoma
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
High-grade B-cell lymphoma with MYC and BCL2 rearrangements arising in a composite lymphoma
Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients
Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
Novel chromatin interactions by structural rearrangements and aberrant enhancer functions drive oncogenic programs in unfavorable neuroblastoma